Fancy Meds, LLC dba Fancy Meds Warning Letter Details

Summary

Fancy Meds, LLC was cited for unlawfully selling unapproved and misbranded compounded drugs (semaglutide and tirzepatide) over the internet in violation of the Federal Food, Drug, and Cosmetic Act. The company's website made false or misleading claims suggesting that its compounded products were equivalent to FDA-approved branded drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, and falsely represented that the compounding process involved FDA monitoring and FDA-approved ingredients. These claims violated sections 502(a) and 502(bb) of the FDCA by misrepresenting non-approved compounded drugs as therapeutically equivalent to approved pharmaceuticals, creating safety and efficacy concerns for consumers.